Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 December 2019 | Story Nonsindiso Qwabe | Photo Barend Nagel
Victoria Read more
Victoria the mannequin has become a familiar face in Nursing classrooms

She has an uncanny ability to move her eyes towards the sound of voices in a room, her voice shrills and squeals when she's in pain, she throws in a Spanish word or two, and she releases bodily fluids just like a real human would. 

These are just some of the quirky characteristics that make up the new R1,76 million-rand birthing mannequin in the School of Nursing's Simulation Unit, who goes by the name Victoria. She weighs more than 80 kg and is almost 1,7 metres high. With features such as real eyelashes, eyebrows, and hair, you can't help but do a double take when you lay eyes on her. 

Students getting practical experience

While the unit has other mannequins used for training Nursing students in each year or their study, Simulation Coordinator from the School of Nursing in the Faculty of Health Sciences, Cecile Fourie, said Victoria was a major upgrade for the school because of her versatility. Victoria would further enhance the school's quality of teaching by training students in their final year of undergraduate studies as well as those pursuing their postgraduate studies, about the ins and outs of pregnancy and other female morbidities, Fourie said. 

"We try to make our scenarios as real and authentic as possible and we've seen how much our students have grown. Introducing Victoria to our pre- and postgraduate students will prepare them to be competent in clinical practice." 

Meet Victoria

So, what exactly can Victoria do? 

Fourie said while the other mannequins were made with screws that made them look robot-like, Victoria was made with silicone and given a clean finish to make her appear life-like. The other mannequins can only blink, but Victoria's eyes move around, she can speak Spanish and French, and she comes with five tummies for different medical scenarios. She has a normal tummy which acts as a closure, an operable tummy for caesarean delivery, a tummy that allows a breeched baby to be twisted and turned from the outside just before delivery, a contraction tummy used for normal vaginal delivery – which also allows Victoria to push, bleed, urinate, and release mineral oil which acts as amniotic fluid. The fifth tummy is postpartum haemorrhage, a condition that is common among South African mothers after delivery. 

"It’s so good that we get to train our students in such real, lifelike circumstances. Through Victoria we're going to try and do our part in lessening maternal deaths, which are so prominent in our country. She can act out all the abnormalities that take place in a real delivery, and she can also have other medical conditions such as a heart attack," Fourie said.



News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept